Abstract
The impact of Alzheimer's disease (AD) on the pupillary light response (PLR) is controversial, being dependent on the stage of the disease and on the experimental pupillometric protocols. The main hypothesis driving pupillometry research in AD is based on the concept that the AD-related neurodegeneration affects both the parasympathetic and the sympathetic arms of the PLR (cholinergic and noradrenergic theory), combined with additional alterations of the afferent limb, involving the melanopsin expressing retinal ganglion cells (mRGCs), subserving the PLR. Only a few studies have evaluated the value of pupillometry as a potential biomarker in AD, providing various results compatible with parasympathetic dysfunction, displaying increased latency of pupillary constriction to light, decreased constriction amplitude, faster redilation after light offset, decreased maximum velocity of constriction (MCV) and maximum constriction acceleration (MCA) compared to controls. Decreased MCV and MCA appeared to be the most accurate of all PLR parameters allowing differentiation between AD and healthy controls while increased post-illumination pupillary response was the most consistent feature, however, these results could not be replicated by more recent studies, focusing on early and pre-clinical stages of the disease. Whether static or dynamic pupillometry yields useful biomarkers for AD screening or diagnosis remains unclear. In this review, we synopsize the current knowledge on pupillometric features in AD and other neurodegenerative diseases, and discuss potential roles of pupillometry in AD detection, diagnosis and monitoring, alone or in combination with additional biomarkers.
Introduction
Dementia is a global epidemic and has become a public health priority. Alzheimer's disease (AD) is the most common cause for dementia worldwide (1), accounting for 50–70% of dementia cases. The two major neuropathological landmarks of AD are deposition of insoluble amyloid-β (Aβ) plaques and formation of neurofibrillary tangles, composed of hyperphosphorylated tau proteins. These pathologic abnormalities are found in the central nervous system, as well as in the retina (2–4). The pathophysiology of AD is poorly understood, but a common hypothesis postulates that aggregation of Aβ is a pre-requisite for tau accumulation, neurodegeneration, and ultimately, to clinical manifestations. Clinical features of AD include progressive cognitive decline, affecting memory, learning, language, visuospatial abilities, and executive functions, but also deterioration of sleep and normal circadian rhythms (5). Most often extensive and largely irreversible neuronal histopathological changes precede clinical features of AD (6), which may explain the current failure of all disease modifying agents in this condition. For these reasons, it is believed that early diagnosis of AD is crucial for early and effective therapeutic interventions, improving AD outcomes.
Several in vivo biomarkers have been proposed for early identification of AD pathology, including brain imaging biomarkers (positron emission tomography after Aβ labeling) (7), as well as fluid biomarkers (within the cerebrospinal fluid and, possibly, in the blood) (8). These, and other novel genetic, biological, deep-learning based, or behavioral biomarkers aim to surpass the current performance of classical clinical evaluations in AD, which are subjective, time-consuming and deliver variable results. The eye, which is embryologically, anatomically, and physiologically an extension of the brain, has been an early explored target for identification of neurodegeneration biomarkers in AD (9, 10). Functionally, various ocular biomarkers have been tested for detection and evaluation of AD, such as eye movement recordings and pupillary responses to light or to cognitive load (9–11). Several studies have suggested that AD may be associated with altered pupillary light responses (PLR), as a consequence of abnormalities in the retina and/or the efferent pupillary system. Several arguments support the possible pupillary involvement in AD, including pathological changes in the retina, as well as existence of parasympathetic (cholinergic) and sympathetic (adrenergic) dysfunctions in the disease. Indeed, neurodegeneration commonly affects the locus coeruleus (LC), located in pons and involved in the sympathetic control of pupil size and PLR (2, 12), as well as the Edinger Westphal nucleus (EWN) (4, 13), involved in the parasympathetic control of the pupil. Pupillometry is an easy, non-invasive and affordable tool, allowing the evaluation of the PLR in AD and other ocular and neurological diseases. Whether static or dynamic pupillometry yields useful biomarkers for AD screening or diagnosis remains unclear. In this review, we synopsize the current knowledge on pupillometric features in AD and other neurodegenerative diseases, and discuss potential roles of pupillometry in AD detection, diagnosis and monitoring, alone or in combination with additional biomarkers.
The Neurophysiology of the Pupillary Light Response
Afferent and Efferent Pathways Governing the Pupillary Light Response
The pupil size is under the control of a closed autonomic loop. The pupil constrictor and dilator muscles receive antagonistic impulses from the parasympathetic (cholinergic) and sympathetic (adrenergic) autonomic nervous systems, respectively (Figure 1). The PLR is also dependent on the integrity of the retina, and in particular on the integrity of the intrinsically photosensitive melanopsin expressing retinal ganglion cells (mRGCs) (15). Although the mRGCs are activated by rods and cones, they are also intrinsically photosensitive through the melanopsin photopigment, subserving the PLR via central projections to the olivary pretectal nucleus (OPN) (16), which projects to the EWN, as demonstrated in non-human primates. The parasympathetic EWN is a cholinergic nucleus in the oculomotor complex, at the origin of preganglionic efferent neurons which synapse in the ciliary ganglion, subsequently innervating the constrictor pupillae (14, 17). The mRGCs also project to the central circadian clock located in the hypothalamic suprachiasmatic nucleus (SCN), which governs various bodily circadian rhythms and projects to the sympathetic locus coeruleus (LC), located in pons (Figure 1) (18, 19) [for review see (20)]. The sympathetic efferent system, including LC and SCN, regulates the resting pupil size at different levels of background illumination (17), by controlling the tone of the dilator muscle. Beyond the intervention of these motor structures, the pupillary size and function can be modulated by supranuclear neuronal influences. Other possible confounding factors, affecting the size of the pupils include the respiration rate (21), emotional status (22), vigilance (23), and age (24).
Figure 1
Retinal Photoreception and Chromatic Pupillometry
Recorded using an infra-red pupilometer, the PLR is governed by rods, cones and mRGCs. The intrinsically photosensitive mRGCs, located in the inner retina, produce a sustained constriction of the pupil in response to bright blue light which persists even after light offset; in addition to integrating signals from rods and cones (25). Different light wavelengths, at different intensities stimulate specifically different retinal photoreceptors (26–29). Thus, chromatic pupillometry, using different wavelengths and light intensities has been used for the evaluation of inner and outer retina integrity, in various conditions (26–29).
Pathophysiology of Light-Induced Pupillary Responses in AD
Cholinergic Deficit in AD
Loss of cholinergic neurons is a common event in AD, possibly leading to alteration of cognitive processes. Specific loss of cholinergic neurons, mainly located in the medial septum and in the para-hippocampal area, is associated with memory impairment (30), but also with other cognitive deficits seen in AD (31, 32). The hypothesis of cholinergic deficit fails however, to explain other impairments in AD, i.e., disruption of circadian rhythms, sleep, and executive functions.
AD affects the cholinergic EWN, which is the central brainstem sub-nucleus of the oculomotor complex, involved in the control of the pupil constriction. Pathologic studies have shown that the EWN is affected even at early stages of AD, displaying deposition of Aβ amyloid plaques and neurofibrillary tangles (4, 13, 33). AD is associated with increased glutaminyl cyclase activity, resulting in formation of highly neurotoxic Aβ amyloid precursors (pyroglutamate Aβ peptide), identified in the EWN and in the preganglionic cholinergic PLR-governing neurons, as well as in other cholinergic neurons in the nucleus basalis of Meynert (34). In AD, the EWN neurons, display a decrease in their total dendritic length per neuron as well as a severe loss of distal dendritic branches and dendritic spines, leading to severe decrease in synaptic contacts (35). It has been suggested that these pathological changes of the EWN may be an early and specific feature of AD and they may result in decreased cholinergic control of pupillary responses (35). Unfortunately, little is known about the involvement of other parasympathetic structures involved in the PLR, i.e., the olivary pretectal nucleus and ciliary ganglia.
Adrenergic Deficit in AD
The LC modulates pupil size in 2 possible ways; by direct stimulation of preganglionic sympathetic neurons, as well as by inhibitory regulation of the EWN (Figure 1) (17, 36). Various factors stimulating the LC may modulate the PLR. For example, anxiety, associated with excitation of the LC (37, 38) or drugs increasing noradrenergic output to the EWN like noradrenaline re-uptake inhibitors (14, 39), lead to an increased sympathetic response on PLR like prolonged latency, reduced amplitude of constriction and faster redilation. Conversely, drugs inhibiting LC activity like clonidine (α2-adrenoceptor agonist) cause pupillary miosis and reduce the sympathetic effect on PLR (40–42). In monkeys, an electrophysiologically detectable activity in LC has been associated with mydriasis at rest (43).
Patients with AD and mild cognitive impairment (MCI), considered as the pre-clinical stage for AD, undergo significant loss of noradrenergic neurons in the LC (55 and 30%, respectively), compared to healthy controls, a finding which may impact the PLR (44). Neuronal loss in the LC of patients with AD may lead to decreased sympathetic supply to the iris and reduce the baseline pupil size (45).
Retinal Changes in AD
Aging is associated with optical (46, 47) photoreceptoral and retinal neuronal changes (48–50). Optically, in spite of decreased lens transmittance for short wavelength blue light in aging and cataract, the mRGCs induced pupillary response by blue light are well-preserved (51–53), and the pupillary responses are reduced irrespective of the wavelength of light. Although, aging has been associated with axonal and retinal ganglion cell loss (54), AD has been associated with greater thinning of retinal nerve fiber layer compared to age matched healthy controls (55–57), suggesting an accelerated loss of RGCs in AD patients. Pathological studies have shown presence of Aβ amyloid plaques in the retina of AD patients (58, 59) including in the inner layers of retina (3). These changes were often associated with blood vessel abnormalities and areas of cellular degeneration, similar to what is seen histologically in the brain of patients with AD (60, 61).
Moreover, retinas of patients with advanced AD display not only histological evidence of mRGC loss, but also selective deposition of Aβ amyloid plaques within these cells, which subserve the PLR (3). Less is known about the early selective loss of mRGC and possible mRGC Aβ deposition, occurring in AD. Occurrence of such a phenomenon should allow discrimination between normal aging patients and AD, using chromatic pupillometry. Chromatic pupillometry has been used in other conditions as a marker of mRGC integrity (62). In primary open angle glaucoma, a condition associated with histological mRGC loss (63), abnormal melatonin secretion profile (64) and sleep and circadian rhythm dysfunction (65), various pupillometric studies have shown abnormal PLR responses (28, 66–70). Conversely, in mitochondrial hereditary optic neuropathies, mRGCs are resistant to neurodegeneration, explaining the relatively preserved chromatic pupillometry parameters (71–73) and melatonin profiles (74). It is possible that mRGC loss, alone or combined with neuronal loss occurring in the suprachiasmatic nuclei, may be associated with circadian rhythm dysfunctions which can occur even at early stages of AD (3, 5).
Features of the Pupillary Light Responses in AD
Baseline Pupil Diameter
The consequence of AD on the pupillary diameter at rest has been controversial in various studies, probably due to methodological differences, i.e., measurement conditions and sample sizes. A few studies with small sample size (range 9 to 23 AD patients) have reported reduced baseline pupillary diameters in AD compared to those of healthy subjects (45, 75–77). Other studies did not find any difference in baseline pupil diameters between AD, MCI and controls (78, 79), however, the groups were not age-matched in the study with largest sample size (n = 66 AD, 42 MCI) (78), while AD patients in the other study were using cholinergic and anti-depressant medications which may alter the baseline pupil size (n = 15 AD) (79). An increased baseline pupillary diameter has also been reported in AD (n = 20 AD), but no details of age of the two groups were mentioned (80) (Table 1).
Table 1
| Study (n = sample size)* | Light paradigm | BPD | LoC | AC | MCV | MCA | Redilation velocity | Comments and features of parasympathetic (PSD) and sympathetic (SD) deficiencies |
|---|---|---|---|---|---|---|---|---|
| Prettyman et al. (45), (n = 9) | 11 × 200 ms 565 nm flashlights at 8.5 × 10−3 and 7 × 10−2 mW/cm−2, 0.43 and 1.84 mW/cm−2 at 1 cm from the eye | ↓ | ↔ | ↓ | NA | NA | ↑ | PSD features: ↓ AC and ↑redilation SD features: In darkness, pupillary dilation amplitude and velocity decreased, along with decreased BPD. |
| Ferrario et al. (80), (n = 20) | 1 s of 660 nm flashlight | ↑ | ↑ | ↔ | ↔ | ↑ | ↔ | PSD: ↑BPD and ↑LoC SD: ↑MCA Limitations: Age of different groups not mentioned. |
| Fotiou et al. (81), (n = 5) | 20 ms flashlight delivered using a xenon lamp at 30 cm from the eye | ↑ | ↔ | NA | NA | NA | NA | PSD: ↑BPD. Cholinergic medications reduced BPD close to controls. |
| Granholm et al. (79), (n = 15) | 16 × 150 ms pulses of light at 20 and 40 lux from a computer screen at 77 cm | ↔ | NA | ↓ | NA | NA | NA | PLR checked after diluted tropicamide test. 9 AD patients were using cholinergic medications and 5 were using anti-depressant medications. |
| Fotiou et al. (75, 76), (n = 23) | 20 ms flashlight delivered using a xenon lamp at 30 cm from the eye | ↓ | ↑ | ↓ | ↓ | ↓ | ↑ | PSD: ↓AC, ↓MCV, ↓MCA, ↑LoC, ↑redilation SD: ↓BPD |
| Frost et al. (77), (n = 19) | 31 ms white flash at 180 μW | ↓ | ↔ | ↓ | ↓ | ↓ | ↑ | PSD: ↓ Mean constriction velocity, ↓MCV, ↓MCA, ↓AC and ↑% redilation at 3.5 s SD: ↓BPD |
| Bittner et al. (78), (n = 66AD, 42MCI) | 40 × 200 ms pulse of 585 nm light at 200 cd/m2 | ↔ | ↔ | ↔ | NA | NA | NA | Controls were younger than AD and MCI patients and had greater constriction amplitude on repetitive stimulations |
| Fotiou et al. (82), (n = 42) | 20 ms flashlight at 24.6 cd/m2 | NA | ↑ | NA | ↓ | ↓ | NA | PSD: ↓ MCV, ↓MCA, ↑LC MCV and MCA correlated well with MMSE scores. |
| Frost et al. (83), (n = 14) | 31 ms white flashlight at 180 μW | NA | NA | ↓ | ↓ | ↓ | NA | Limitations: Controls were younger than AD patients. |
| Van Stavern et al. (84), (n = 24) | 3 × 525 ms white flashlight at 180 W | NA | ↔ | ↔ | NA | NA | ↔ | Preclinical AD patients with no cognitive impairment were studied. |
Summary of studies on PLR in AD.
BPD, baseline pupillary diameter in mm; LoC, latency of constriction in seconds; AC, amplitude of constriction; MCV, Maximum constriction velocity; MCA, maximum constriction acceleration; AD, Alzheimer's disease; PSD, Parasympathetic deficiency; SD, Sympathetic deficiency; ↓, decreased; ↑, increased; ↔, Not significant; NA, Not applicable/available; PLR, pupillary light response; MMSE, Mini-Mental State Examination;
n, Sample size of patients included in the study (excluding controls).
Constriction Phase
Most pupillometric studies in patients with AD have reported results compatible with parasympathetic deficiency, translating to increased latency of pupillary constriction to light, decreased constriction amplitude, reduced mean constriction velocity and faster redilation after light offset (45, 75, 76, 83, 85) (Table 1). Pupil constriction velocity is obtained as the first derivative of change in pupil size with respect to time and acceleration as the second derivative (change in constriction velocity with respect to time) (Figure 2). Patients with AD typically display decreased maximum velocity of constriction (MCV) and maximum constriction acceleration (MCA) compared to controls, suggesting a parasympathetic deficiency. Amongst all pupillometric features, MCA and MCV have been reported as the most accurate parameters to differentiate AD patients from healthy controls (75, 76, 83). Nonetheless, other studies have failed to find such differences between AD patients and healthy individuals (78, 80). These differences may be the result of the different illumination protocols used, since studies using white light typically are associated with larger constriction amplitudes and shorter latencies (24), compared to studies using red light at 660 nm (80) or 585 nm (78). Considering that different studies have used different intensity and wavelength stimuli, this effect cannot be completely attributed to the wavelength alone. However, other studies have demonstrated that when photon density is kept constant, shorter wavelength light produced greater constriction amplitude than longer wavelength (86, 87).
Figure 2
In a recent study in cognitively normal pre-clinical AD subjects, diagnosed on the basis of high cortical binding potential of Aβ amyloid on PET imaging and/or low CSF Aβ amyloid levels, there was no significant difference in any of the pupillary parameters in response to light emitting diodes (LEDs) producing a white flash of 180 W for 525 ms, compared to healthy controls (84). Only a marginal difference was observed in PLR in pre-clinical stages, suggesting that the effect of AD on PLR in pre-clinical stages is very small and may not be detectable. This suggests that PLR using achromatic light stimulus may be a valid biomarker for established Alzheimer's disease but it may have limited clinical utility in screening for AD in pre-clinical stages, perhaps due to the very small disease effect on PLR (84).
A pupillometric study, using non-Maxwellian retinal stimulation with repetitive, brief, long wavelength light (585 nm), aimed to compare patients with MCI, AD and normal controls, but failed to find inter-group differences (evaluating baseline diameters, constriction amplitudes, and constriction latencies), after adjustment for age (78). However, the use of specific repetitive light stimuli induced stronger pupillary responses in controls in terms of relative constriction amplitude (difference in the PLR measurements of the first and last stimuli), compared to AD and MCI patients, suggesting that repetitive pupillary stimulation might be a more appropriate stimulus to discriminate patients with AD and MCI from controls (78). It was proposed that repetitive stimuli caused a fatigue of the sympathetic inhibitory system to the parasympathetic pathway revealing the true effect of parasympathetic system alone on PLR. Smaller relative miosis and amplitude of constriction in AD patients suggests a decreased parasympathetic innervation to the pupillary system which may not be detected in the presence of inhibitory sympathetic system. Although relative amplitude was independent of age, the difference between MCI and control groups was not statistically significant while between AD and controls may fail to reach statistical significance if Bonferroni correction is applied. Moreover, its definition and calculation is not clearly explained in the study. Constriction phase due to different wavelength light stimuli in AD patients has not been studied yet.
Pupillary Redilation Phase
The pupillary redilation phase has been explored in several studies, but these results are sometimes difficult to compare, given the variable definitions of this parameter such as (i) percentage of pupillary redilation after 3.5 s of white flash light offset (75–77), (ii) 75% redilation time (45, 77), and (iii) average dilation velocity (77, 84). The majority of these studies have reported a faster pupillary redilation phase [analogous to decreased Post-illumination pupil response (PIPR)] in AD patients compared to controls, making it the most consistent PLR feature in AD patients (45, 75–77). In a study which extensively studied the redilation phase, the percentage recovery at 3.5 s and the 75% redilation time was significantly greater in AD patients compared to aging controls. Although the mean dilation velocity (mm/sec) was slower in AD patients, it can be ignored since the pupil size was not calculated as a percentage of baseline pupil diameter which was significantly smaller in AD (77). A recent study in preclinical AD alone did not find a significant increase in dilation velocity compared to controls following an achromatic light stimulus, however, it is not clear whether the measurements were adjusted to baseline pupil diameter (84). The faster pupillary redilation after light offset has been attributed to the diminished parasympathetic tonus associated with the cholinergic deficit, translating into failure to maintain a tonic pupillary constriction. An alternative explanation, which was not yet considered in previous studies, is that the accelerated pupillary redilation may be the result of selective mRGC loss in AD, causing an abnormal, faster PIPR as seen in other conditions affecting the mRGC, such as glaucoma (66). This hypothesis is in line with the findings of another study, which did not find any difference of the redilation phase between a group of AD patients and controls, after exposure to red light (660 nm) (80). Indeed, red light at medium high intensities is less prone to stimulate the mRGC and might have failed to explore their dysfunction. Although, redilation was not found to be different in preclinical AD patients in a recent study using a 180 W achromatic stimulus for 525 ms (84), chromatic pupillometry studying different parameters like constriction amplitude or PIPR to blue light, can still be a viable option in such cases due to selective mRGCs loss as reported in AD patients (3). No study till date has investigated pupillometric signs of mRGC dysfunction or impaired PIPR to blue light in AD patients and needs to be explored in the future. However, these interpretations are speculative, it is well-possible that the faster redilation in AD patients may be the result of an interplay between the two factors, i.e., the mRGC loss and the cholinergic deficit. It is noticeable that mRGC loss in AD should result in selective faster redilation after offset of blue light (460 nm), which specifically stimulates the mRGCs. On the opposite, faster redilation due to cholinergic deficiency should be independent of wavelength of stimulus used, occurring after offset of both blue and red light. Future studies taking into account these factors, should be able to disentangle the respective role of the afferent vs. efferent system in the pupillary redilation phase.
A Potential Role for Pupillometry in a Multi-Modal Approach for Detecting AD?
Generic Screening and Diagnostic Tests for AD
The gold standard for AD diagnosis is still based on pathology findings. However, in clinical practice, screening for AD or cognitive impairment uses various questionnaires and interactive tests, including the Mini Mental Scoring Examination (MMSE) or the Montreal cognitive assessment test (MoCA). These tests have numerous limitations, including language barriers, geographical adaptability, subjectivity, long implementation time, and the necessity for constant supervision by trained and skilled personnel. Several objective tests have been developed for early AD detection and diagnosis including cerebro-spinal fluid (CSF) analysis to measure beta amyloid (Aβ), total tau proteins and phosphorylated tau peptides quantification (8, 88), and magnetic resonance imaging (MRI) imaging of the brain and positron emission tomography (PET) scan measuring the brain Aβ plaque burden (6, 7, 89). These modalities are expensive, invasive and potentially dangerous (90, 91). In addition, they detect only structural and not functional changes in AD.
From the published studies, pupillometric evaluations may not suffice for early AD detection. However, they may constitute an adjunctive method in a, multimodal approach, combining (i) novel, cognitive, visuospatial, and memory tests involving portable virtual reality devices, (ii) retinal imaging for detection of neuronal loss and/or amyloid deposition, and (iii) objective functional outcomes provided by targeted color pupillometry.
PLR and Genetic Mutations
Apolipoprotein E is a fat-binding protein involved in the metabolism of fat, produced by APOE gene found on chromosome 19, being the only genetic factor associated with the common late onset AD. APOE mutation is not a causative mutation, but is rather considered as a risk factor for AD (92, 93). Although the PLR is not directly influenced by the APOE ε4 carrier status (78), their combination may increase the area under the curve for the combined test performance (83).
A pupillometric study has evaluated participants from a single family harboring an Amyloid-Beta Precursor Protein genetic mutation (APPGlu693Gln) (6 carriers with no cognitive impairment and 6 non-carriers) (94). This mutation results in a rare form of autosomal dominant Alzheimer's disease with phenotypical penetration approaching 100% and which is responsible for an early onset of AD. The pupillometric assessment yielded a slower pupil 75% recovery time in mutation carriers compared to non-mutation carriers. Globally, pupillometric changes were detected in pre-symptomatic carriers of the mutations, but were not statistically significant.
PLR and Cognitive Assessment Tools
MMSE is routinely used to screen elderly subjects for dementia and has a AUROC of 0.89 (95). PLR in patients with AD having higher MMSE and Wechsler Memory Scale (better cognition) scores correlated moderately with MCV, MCA and latency of constriction (82). On repetitive pupillary stimulation, higher MMSE correlated with larger increase in amplitude and relative amplitude and greater decrease in the latency (p < 0.05) of constriction (78). These outcomes suggest that the pupillary light response may depend on the severity of the disease and can be used for monitoring the disease progression. However, combined efficacy of MMSE and PLR has not been explored as both tools are practical, easy, non-invasive, and affordable and may yield better accuracy if combined together, compared to individual outcomes.
PLR and CSF Abnormalities
Decrease in pupillary constriction amplitude with repetitive stimulation in AD patients correlated with lower Aβ42 protein levels (p = 0.01) and a trend with higher tau levels in CSF (p = 0.08) (78). This suggests a possible association between cholinergic deficit, decreased Aβ42 protein levels and a trend with higher tau levels in CSF which supports a causative role of Aβ amyloid plaques in central cholinergic deficit (92). To date, the efficacy of a combined PLR-CSF screening method remains unknown.
PLR and Topical Weak Anticholinergic Eye Drops
In a highly controversial study, Scinto et al. reported that patients with AD exhibit larger pupil dilation compared to age-matched controls after instillation of diluted anticholinergic eyedrops (Tropicamide 0.01%) (96) Several studies have contradicted this finding (97–99) which could be due to ethnicity, age, ocular penetration of drug, properties of the solution and background luminance (79). A combination of topical weak anticholinesterase and PLR showed significant reduction in constriction amplitude for AD and Parkinson's patients compared to controls, but no significant difference between Alzheimer's and Parkinson's patients was found, while latency of constriction was similar within the 3 groups (79). However, others did not find any such significant difference in PLR pre or post weak anticholinergic eyedrops use, between AD patients and controls (80). Hence, the use of weak anticholinergic eyedrops may not improve the efficacy of PLR in detecting AD, since it may not give consistent results and decrease in amplitude of constriction is noted in AD even without using topical anticholinesterase.
Limitations of Previous Pupillometric Studies in AD
Most of the previously published pupillometric studies in AD have various methodologic limitations. The intensity, light wavelength and duration of light exposure were variable in all the above mentioned studies. Yet, these parameters can affect, independently, or in combination, the PLR outcomes (24, 100). Therefore, there is a high need for standardization of experimental conditions in AD studies, similar to what has been described in studies using light therapy (101) and in other animal studies (102). Most current pupillometric studies agree of the need for standardized analysis of baseline pupil diameters (103, 104). Interestingly, most of the previous PLR studies in AD have not normalized the baseline diameter in their subjects, making any comparison very difficult. In a few studies evaluating pupillometric results in AD, there was no age-matching between the groups of patients and controls (78, 79, 83). Indeed, the decreased pupillary diameter with age (105, 106) may constitute a confounding factor. Last, but not least, the severity of AD was rarely taken into account in the evaluation of the PLR.
Effect of Cholinergic Medications
Only a few, small sample studies have reported the effect on the PLR of cholinergic drugs, commonly used in AD (79, 81). Thus, AD patients without cholinergic medications displayed larger baseline pupillary diameter, reduced pupillary miosis and higher number of oscillations at rest, compared to AD patients on cholinergic treatments and to healthy controls. Patients on medications had a greater latency of onset of constriction compared to both the controls and the medication free AD patients (81). However, other study in AD patients, have not found an effect of cholinergic medications on pupillary miosis but supported the increase in latency of constriction (79). PLR in AD patients on cholinergic medications behaved more like controls with no significant difference in constriction amplitude and baseline pupil diameter than their medication free counterparts (81). Taken together, these findings suggest that cholinergic medications might improve the pupillary responses in AD patients. Due to the very small sample size of these studies, it is difficult to conclude regarding a possible effect of cholinergic medications on the PLR in these patients. Additional studies are needed to understand the effect of cholinergic medications on PLR.
Effect of Ocular Co-morbidities
The most common ocular condition associated with aging is cataract which can attenuate the PLR response to both red and blue light. But the senescence of the lens does not selectively reduce the mRGCs responses to intense blue light and is well-preserved, in spite of its decreased lens transmittance in aging and cataract (51). Different retinal and optic nerve conditions can affect PLR and using chromatic pupillometry it is possible to localize the loss of photoreceptoral function i.e., inner or outer retina (107). Primary open angle glaucoma is associated with decreased PLR in response to exposure to both red and blue light with decreased PIPR for blue light (28, 70), while retinal dystrophies affecting rods and cones lead to decreased PLR responses to red and low intensity blue light with an increased PIPR to bright blue light stimulus (108, 109). Diabetic retinopathy and age-related macular degeneration can also affect the PLR (110, 111), but there is little indication to what extent these PLR alterations might be disease-specific, or whether they may confound co-existence of AD in the aging population.
PLR in Other Neurodegenerative Disorders
Autonomic nervous system dysfunction has been described in Parkinson's disease (PD) (112), including cholinergic deficit (113), Various PLR abnormalities have been described in PD, including reduced amplitude of constriction, increased latency and decreased velocity and acceleration of constriction, while the baseline pupil diameter may be increased or not significantly different compared to healthy controls (Table 2) (76, 114). Pupillary unrest has also been increased in PD patients which were not on medications compared to healthy individuals or in treated patients (115), Pupillary redilation has not been significantly different in PD studies using white flash light stimuli (114, 115). However, a recent chromatic pupillometry study in PD patients has suggested that the PIPR following a short wavelength blue light elicits a faster redilation compared to healthy controls. This finding is consistent with loss of mRGCs in PD (116), possibly related to deposition of α-synuclein in the retinal ganglion cells in the inner plexiform layer of the retina (117, 118). An alternative explanation might be related to reduction in the dopamine expression in the amacrine cells which relay information from rods and cones to mRGCS.
Table 2
| Study (n = sample size)* | Light paradigm | BPD | LoC | AC | MCV | MCA | Redilation velocity | Comments and features of parasympathetic (PSD) and sympathetic (SD) deficiencies | |
|---|---|---|---|---|---|---|---|---|---|
| Micieli et al. (114), (n = 23) | 500 ms flashes of white light at 1,400 lux | ↔ | ↑ | ↓ | NA | NA | ↔ | BPD in dark was not significantly different from controls but in photopic conditions, pupillary diameter was significantly larger in PD patients. PSD: ↑LoC, ↓AC | |
| Granholm et al. (79), (n = 15) | 16 × 150 ms pulses of light at 20 and 40 lux from a computer screen at 77 cm | ↔ | NA | ↓ | NA | NA | NA | PLR checked before and after diluted tropicamide test. | |
| Fotiou et al. (76), (n = 22) | 20 ms flashlight delivered using a xenon lamp at 30 cm from the eye | ↔ | ↑ | ↓ | ↓ | ↓ | NA | PSD: ↓AC, ↓MCV, ↓MCA, ↑LoC, ↑redilation SD: ↓BPD | |
| Jain et al. (115), (n = 17) | 11 × 1 s white flashlight at 13 cd/m2, subtending a visual angle of 4.60° at a distance of 73 cm | NA | NA | NA | ↔ | NA | ↔ | Pupillary unrest was significantly higher suggestive of autonomic dysfunction. Five patients were on dopaminergic medications. | |
| Joyce et al. (116), (n = 17) | 8 s pulsed and 12 s 0.5 Hz sinusoidal stimulations using 465 nm and 638 nm lights at 15.1 log photons/cm2.s at the corneal level | Blue Red | NA NA | NA NA | ↔↓ | NA NA | NA NA | ↑↔ | Selective faster redilation to short wavelength light suggests mRGC dysfunction. |
Summary of studies on PLR in PD.
BPD, baseline pupillary diameter in mm; LoC, latency of constriction in seconds; AC, amplitude of constriction; MCV, Maximum constriction velocity; MCA, maximum constriction acceleration; PD, Parkinson's disease; PSD, Parasympathetic deficiency; SD, Sympathetic deficiency; ↓, decreased; ↑, increased; ↔, Not significant; NA, Not applicable/available; mRGC, Melanopsin expressing retinal ganglion cells; PLR, pupillary light response;
n, Sample size of patients included in the study (excluding controls).
Autonomic nervous system dysfunction has also been described in dementia with Lewy bodies and to a lesser extent in fronto-temporal dementia, which can be associated with retinal abnormalities (119, 120). However, the specific effects of autonomic dysfunctions and retinal changes on pupillary light reflexes have not yet been studied in these disorders.
Summary
In summary, MCV and MCA appear to be the most accurate PLR features, but also the least studied, while redilation velocity/rate (corresponding to PIPR) appears to be the most consistently altered PLR feature in AD. In conjunction with other features (baseline pupillary diameter, amplitude and latency of constriction), these parameters predominantly suggest parasympathetic deficiency, associated with mRGCs dysfunction. Longitudinal and adequately designed studies are necessary to validate the use of pupillometry in the early detection and follow-up of AD. Further studies are needed to establish the respective contribution of retinal (afferent) vs. efferent pupillary pathways in the alteration of the pupillary responses, for which chromatic pupillometry can potentially be used and translated into clinical application. Studies may also be designed to investigate the effect of cholinergic medication on PLR in AD patients and the potential use of artificial intelligence on pupillometric traces and video recordings. Using low-cost hardware, pupillometry can now easily be implemented in both remote tele-ophthalmology settings (121), as well as in continuous home monitoring (122). Combined with cognitive game-based investigations and wearables (123, 124), pupillometry may allow a more accurate screening, follow-up, and management of patients with AD.
Statements
Author contributions
PC conducted the review of literature. PC, DM, and RN wrote the manuscript. All authors (PC, RN, DM, MF, and NK) reviewed and approved the manuscript.
Funding
This work was supported by the National Medical Research Council, Singapore (NMRC/CIRG/1401/2014) to DM.
Conflict of interest
DM has a patent application based on a pupillometry protocol (PCT/SG2015/050494): A method and system for monitoring and/or assessing pupillary responses. DM and RN have a patent application based on a hand held device for ophthalmic and neurological screening (PCT/SG2018/050204): Hand held ophthalmic and neurological screening device. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
PrinceMJacksonMJFerriDCPSousaRAlbaneseDERibeiroMWSet al. World Alzheimer Report 2009. Alzheimer's Disease International (2009).
2.
BondareffWMountjoyCQRothMRossorMNIversenLLReynoldsGPet al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord. (1987) 1:256–62. 10.1097/00002093-198701040-00005
3.
La MorgiaCRoss-CisnerosFNKoronyoYHannibalJGallassiRCantalupoGet al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. (2016) 79:90–109. 10.1002/ana.24548
4.
ScintoLFWuCKFirlaKMDaffnerKRSaroffDGeulaC. Focal pathology in the Edinger-Westphal nucleus explains pupillary hypersensitivity in Alzheimer's disease. Acta Neuropathol. (1999) 97:557–64.
5.
WuY-HSwaabDF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. (2007) 8:623–36. 10.1016/j.sleep.2006.11.010
6.
VillemagneVLBurnhamSBourgeatPBrownBEllisKASalvadoOet al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. (2013) 12:357–67. 10.1016/s1474-4422(13)70044-9
7.
MorrisJCRoeCMGrantEAHeadDStorandtMGoateAMet al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. (2009) 66:1469–75. 10.1001/archneurol.2009.269
8.
BlennowKHampelHWeinerMZetterbergH. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. (2010) 6:131–44. 10.1038/nrneurol.2010.4
9.
LeruezSAnnweillerCEtcharry-BouyxFVernyCBeauchetOMileaD. Les troubles visuels au cours de la maladie d'Alzheimer. J Français Ophtalmol. (2012) 35:308–11. 10.1016/j.jfo.2011.11.003
10.
JavaidFZBrentonJGuoLCordeiroMF. Visual and ocular manifestations of Alzheimer's disease and their use as biomarkers for diagnosis and progression. Front Neurol. (2016) 7:55. 10.3389/fneur.2016.00055
11.
GranholmELPanizzonMSElmanJAJakAJHaugerRLBondiMWet al. Pupillary responses as a biomarker of early risk for Alzheimer's disease. J Alzheimer Dis. (2017) 56:1419–28. 10.3233/jad-161078
12.
TomlinsonBEIrvingDBlessedG. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci. (1981) 49:419–28. 10.1016/0022-510X(81)90031-9
13.
ScintoLFFroschMWuCKDaffnerKRGediNGeulaC. Selective cell loss in Edinger-Westphal in asymptomatic elders and Alzheimer's patients. Neurobiol Aging. (2001) 22:729–36. 10.1016/s0197-4580(01)00235-4
14.
SamuelsERSzabadiE. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropharmacol. (2008) 6:254–85. 10.2174/157015908785777193
15.
HattarSLiaoH-WTakaoMBersonDMYauK-W. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science. (2002) 295:1065–70. 10.1126/science.1069609
16.
HannibalJKankipatiLStrangCEPetersonBBDaceyDGamlinPD. Central projections of intrinsically photosensitive retinal ganglion cells in the macaque monkey. J Comp Neurol. (2014) 522:Spc1. 10.1002/cne.23555
17.
SzabadiE. Modulation of physiological reflexes by pain: role of the locus coeruleus. Front Integr Neurosci. (2012) 6:94. 10.3389/fnint.2012.00094
18.
GooleyJJLuJFischerDSaperCB. A broad role for melanopsin in nonvisual photoreception. J Neurosci. (2003) 23:7093–106. 10.1523/JNEUROSCI.23-18-07093.2003
19.
LuJShiromaniPSaperCB. Retinal input to the sleep-active ventrolateral preoptic nucleus in the rat. Neuroscience. (1999) 93:209–14. 10.1016/S0306-4522(99)00094-9
20.
NajjarRPZeitzerJM. Chapter 2—anatomy and physiology of the circadian system. In: MiglisMG, editor. Sleep and Neurologic Disease.San Diego: Academic Press (2017). p. 29–53. Available online at: http://www.sciencedirect.com/science/article/pii/B9780128040744000029
21.
OhtsukaKAsakuraKKawasakiHSawaM. Respiratory fluctuations of the human pupil. Exp Brain Res. (1988) 71:215–7. 10.1007/BF00247537
22.
BradleyMMMiccoliLEscrigMALangPJ. The pupil as a measure of emotional arousal and autonomic activation. Psychophysiology. (2008) 45:602–7. 10.1111/j.1469-8986.2008.00654.x
23.
Brink RL vandenMurphyPRNieuwenhuisS. Pupil diameter tracks lapses of attention. PLoS ONE. (2016) 11:e0165274. 10.1371/journal.pone.0165274
24.
Lobato-RincónL-LCabanillas-Campos M delCBonnin-AriasCChamorro-GutiérrezEMurciano-CespedosaASánchez-Ramos RodaC. Pupillary behavior in relation to wavelength and age. Front Hum Neurosci. (2014) 8:221. 10.3389/fnhum.2014.00221
25.
HattarSLucasRJMrosovskyNThompsonSDouglasRHHankinsMWet al. Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice. Nature. (2003) 424:75–81. 10.1038/nature01761
26.
KardonRAndersonSCDamarjianTGGraceEMStoneEKawasakiA. Chromatic pupil responses: preferential activation of the melanopsin-mediated versus outer photoreceptor-mediated pupil light reflex. Ophthalmology. (2009) 116:1564–73. 10.1016/j.ophtha.2009.02.007
27.
KawasakiACrippaSVKardonRLeonLHamelC. Characterization of pupil responses to blue and red light stimuli in autosomal dominant retinitis pigmentosa due to NR2E3 mutation. Invest Ophthalmol Vis Sci. (2012) 53:5562–9. 10.1167/iovs.12-10230
28.
RukminiAVMileaDBaskaranMHowACPereraSAAungTet al. Pupillary responses to high-irradiance blue light correlate with glaucoma severity. Ophthalmology. (2015) 122:1777–85. 10.1016/j.ophtha.2015.06.002
29.
ParkJCMouraALRazaASRheeDWKardonRHHoodDC. Toward a clinical protocol for assessing rod, cone, and melanopsin contributions to the human pupil response. Invest Ophthalmol Vis Sci. (2011) 52:6624–35. 10.1167/iovs.11-7586
30.
CraigLAHongNSKoppJMcDonaldRJ. Selective lesion of medial septal cholinergic neurons followed by a mini-stroke impairs spatial learning in rats. Exp Brain Res. (2009) 193:29–42. 10.1007/s00221-008-1592-5
31.
BartusRT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. (2000) 163:495–529. 10.1006/exnr.2000.7397
32.
BartusRTDeanRLBeerBLippaAS. The cholinergic hypothesis of geriatric memory dysfunction. Science. (1982) 217:408–14. 10.1126/science.7046051
33.
HunterS. The rostral mesencephalon in Parkinson's disease and Alzheimer's disease. Acta Neuropathol. (1985) 68:53–8.
34.
MorawskiMHartlage-RübsamenMJägerCWaniekASchillingSSchwabCet al. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease. Acta Neuropathol. (2010) 120:195–207. 10.1007/s00401-010-0685-y
35.
MavroudisIAMananiMGPetridesFPetsoglouCNjauSNCostaVGet al. Dendritic and spinal alterations of neurons from Edinger-Westphal nucleus in Alzheimer's disease. Folia Neuropathol. (2014) 52:197–204. 10.5114/fn.2014.43791
36.
SamuelsERSzabadiE. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part i: principles of functional organisation. Curr Neuropharmacol. (2008) 6:235–53. 10.2174/157015908785777229
37.
BakesABradshawCMSzabadiE. Attenuation of the pupillary light reflex in anxious patients. Br J Clin Pharmacol. (1990) 30:377–81. 10.1111/j.1365-2125.1990.tb03787.x
38.
BitsiosPSzabadiEBradshawCM. The inhibition of the pupillary light reflex by the threat of an electric shock: a potential laboratory model of human anxiety. J Psychopharmacol. (1996) 10:279–87. 10.1177/026988119601000404
39.
TheofilopoulosNMcDadeGSzabadiEBradshawCM. Effects of reboxetine and desipramine on the kinetics of the pupillary light reflex. Br J Clin Pharmacol. (1995) 39:251–5. 10.1111/j.1365-2125.1995.tb04444.x
40.
AbercrombieEDJacobsBL. Microinjected clonidine inhibits noradrenergic neurons of the locus coeruleus in freely moving cats. Neurosci Lett. (1987) 76:203–8.
41.
BitsiosPSzabadiEBradshawCM. The effects of clonidine on the fear-inhibited light reflex. J Psychopharmacol. (1998) 12:137–45. 10.1177/026988119801200204
42.
CliffordJMDayMDOrwinJM. Reversal of clonidine induced miosis by the alpha 2-adrenoreceptor antagonist RX 781094. Br J Clin Pharmacol. (1982) 14:99–101. 10.1111/j.1365-2125.1982.tb04941.x
43.
JoshiSLiYKalwaniRMGoldJI. Relationships between pupil diameter and neuronal activity in the locus coeruleus, colliculi, and cingulate cortex. Neuron. (2016) 89:221–34. 10.1016/j.neuron.2015.11.028
44.
KellySCHeBPerezSEGinsbergSDMufsonEJCountsSE. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer's disease. Acta Neuropathol Commun. (2017) 5:8. 10.1186/s40478-017-0411-2
45.
PrettymanRBitsiosPSzabadiE. Altered pupillary size and darkness and light reflexes in Alzheimer's disease. J Neurol Neurosurg Psychiatry. (1997) 62:665–8.
46.
NajjarRPTeikariPCornutP-LKnoblauchKCooperHMGronfierC. Heterochromatic flicker photometry for objective lens density quantification. Invest Ophthalmol Vis Sci. (2016) 57:1063–71. 10.1167/iovs.15-18642
47.
TeikariPNajjarRPKnoblauchKDumortierDCornutP-LDenisPet al. Refined flicker photometry technique to measure ocular lens density. J Opt Soc Am A. (2012) 29:2469–78. 10.1364/JOSAA.29.002469
48.
FreundPRWatsonJGilmourGSGaillardFSauvéY. Differential changes in retina function with normal aging in humans. Doc Ophthalmol. (2011) 122:177–90. 10.1007/s10633-011-9273-2
49.
GerthCGarciaSMMaLKeltnerJLWernerJS. Multifocal electroretinogram: age-related changes for different luminance levels. Graefes Arch Clin Exp Ophthalmol. (2002) 240:202–8. 10.1007/s00417-002-0442-6
50.
SongHChuiTYPZhongZElsnerAEBurnsSA. Variation of cone photoreceptor packing density with retinal eccentricity and age. Invest Ophthalmol Vis Sci. (2011) 52:7376–84. 10.1167/iovs.11-7199
51.
RukminiAVMileaDAungTGooleyJJ. Pupillary responses to short-wavelength light are preserved in aging. Sci Rep. (2017) 7:43832. 10.1038/srep43832
52.
NajjarRPChiquetCTeikariPCornutP-LClaustratBDenisPet al. Aging of non-visual spectral sensitivity to light in humans: compensatory mechanisms?PLoS ONE. (2014) 9:e85837. 10.1371/journal.pone.0085837
53.
DaneaultVVandewalleGHébertMTeikariPMureLSDoyonJet al. Does pupil constriction under blue and green monochromatic light exposure change with age?J Biol Rhythms. (2012) 27:257–64. 10.1177/0748730412441172
54.
EsquivaGLaxPPérez-SantonjaJJGarcía-FernándezJMCuencaN. Loss of melanopsin-expressing ganglion cell subtypes and dendritic degeneration in the aging human retina. Front Aging Neurosci. (2017) 9:79. 10.3389/fnagi.2017.00079
55.
BerishaFFekeGTTrempeCLMcMeelJWSchepensCL. Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci. (2007) 48:2285–9. 10.1167/iovs.06-1029
56.
ChanVTTSunZTangSChenLJWongAThamCCet al. Spectral-domain OCT measurements in Alzheimer's disease: a systematic review and meta-analysis. Ophthalmology. (2018) 126:497–510. 10.1016/j.ophtha.2018.08.009
57.
CunhaJPProençaRDias-SantosAAlmeidaRÁguasHAlvesMet al. OCT in Alzheimer's disease: thinning of the RNFL and superior hemiretina. Graefes Arch Clin Exp Ophthalmol. (2017) 255:1827–35. 10.1007/s00417-017-3715-9
58.
AlexandrovPNPogueABhattacharjeeSLukiwWJ. Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer's disease. Neuroreport. (2011) 22:623–7. 10.1097/wnr.0b013e3283497334
59.
Koronyo-HamaouiMKoronyoYLjubimovAVMillerCAKoMKBlackKLet al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. (2011) 54 (Suppl. 1):S204–17. 10.1016/j.neuroimage.2010.06.020
60.
KoronyoYBiggsDBarronEBoyerDSPearlmanJAAuWJet al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. JCI Insight. (2017) 2:93621. 10.1172/jci.insight.93621
61.
TsaiYLuBLjubimovAVGirmanSRoss-CisnerosFNSadunAAet al. Ocular changes in TgF344-AD rat model of Alzheimer's disease. Invest Ophthalmol Vis Sci. (2014) 55:523–34. 10.1167/iovs.13-12888
62.
LucasRJHattarSTakaoMBersonDMFosterRGYauK-W. Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice. Science. (2003) 299:245–7. 10.1126/science.1077293
63.
ObaraEAHannibalJHeegaardSFahrenkrugJ. Loss of melanopsin-expressing retinal ganglion cells in severely staged glaucoma patients. Invest Ophthalmol Vis Sci. (2016) 57:4661–7. 10.1167/iovs.16-19997
64.
KimJYJeongARChinHSKimNR. Melatonin levels in patients with primary open-angle glaucoma with high or low intraocular pressure. J Glaucoma. (2019) 28:154–60. 10.1097/IJG.0000000000001130
65.
GubinDGMalishevskayaTNAstakhovYSAstakhovSYCornelissenGKuznetsovVAet al. Progressive retinal ganglion cell loss in primary open-angle glaucoma is associated with temperature circadian rhythm phase delay and compromised sleep. Chronobiol Int. (2019) 36:564–77. 10.1080/07420528.2019.1566741
66.
KankipatiLGirkinCAGamlinPD. The post-illumination pupil response is reduced in glaucoma patients. Invest Ophthalmol Vis Sci. (2011) 52:2287–92. 10.1167/iovs.10-6023
67.
FeiglBMattesDThomasRZeleAJ. Intrinsically photosensitive (melanopsin) retinal ganglion cell function in glaucoma. Invest Ophthalmol Vis Sci. (2011) 52:4362–7. 10.1167/iovs.10-7069
68.
NissenCSanderBMileaDKolkoMHerbstKHamardPet al. Monochromatic pupillometry in unilateral glaucoma discloses no adaptive changes subserved by the ipRGCs. Front Neurol. (2014) 5:15. 10.3389/fneur.2014.00015
69.
AdhikariPZeleAJThomasRFeiglB. Quadrant field pupillometry detects melanopsin dysfunction in glaucoma suspects and early glaucoma. Sci Rep. (2016) 6:33373. 10.1038/srep33373
70.
NajjarRPSharmaSAtalayERukminiAVSunCLockJZet al. Pupillary responses to full-field chromatic stimuli are reduced in patients with early-stage primary open-angle glaucoma. Ophthalmology. (2018) 125:1362–1371. 10.1016/j.ophtha.2018.02.024
71.
KawasakiAHerbstKSanderBMileaD. Selective wavelength pupillometry in Leber hereditary optic neuropathy. Clin Experiment Ophthalmol. (2010) 38:322–4. 10.1111/j.1442-9071.2010.02212.x
72.
MouraALANagyBVLa MorgiaCBarboniPOliveiraAGFSalomãoSRet al. The pupil light reflex in Leber's hereditary optic neuropathy: evidence for preservation of melanopsin-expressing retinal ganglion cells. Invest Ophthalmol Vis Sci. (2013) 54:4471–7. 10.1167/iovs.12-11137
73.
LooJLSinghalSRukminiAVTowSAmati-BonneauPProcaccioVet al. Multiethnic involvement in autosomal-dominant optic atrophy in Singapore. Eye. (2017) 31:475–80. 10.1038/eye.2016.255
74.
La MorgiaCRoss-CisnerosFNSadunAAHannibalJMunariniAMantovaniVet al. Melanopsin retinal ganglion cells are resistant to neurodegeneration in mitochondrial optic neuropathies. Brain. (2010) 133 (Pt 8):2426–38. 10.1093/brain/awq155
75.
FotiouDFBrozouCGHaidichA-BTsiptsiosDNakouMKabitsiAet al. Pupil reaction to light in Alzheimer's disease: evaluation of pupil size changes and mobility. Aging Clin Exp Res. (2007) 19:364–71. 10.1007/bf03324716
76.
FotiouDFStergiouVTsiptsiosDLithariCNakouMKarlovasitouA. Cholinergic deficiency in Alzheimer's and Parkinson's disease: evaluation with pupillometry. Int J Psychophysiol. (2009) 73:143–9. 10.1016/j.ijpsycho.2009.01.011
77.
FrostSKanagasingamYSohrabiHBourgeatPVillemagneVRoweCCet al. Pupil response biomarkers for early detection and monitoring of Alzheimer's disease. Curr Alzheimer Res. (2013) 10:931–9. 10.2174/15672050113106660163
78.
BittnerDMWieselerIWilhelmHRiepeMWMüllerNG. Repetitive pupil light reflex: potential marker in Alzheimer's disease?J Alzheimers Dis. (2014) 42:1469–77. 10.3233/jad-140969
79.
GranholmEMorrisSGalaskoDShultsCRogersEVukovB. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. Int J Psychophysiol. (2003) 47:95–115. 10.1016/s0167-8760(02)00122-8
80.
FerrarioEMolaschiMVillaLVarettoOBogettoCNuzziR. Is videopupillography useful in the diagnosis of Alzheimer's disease?Neurology. (1998) 50:642–4.
81.
FotiouFFountoulakisKNTsolakiMGoulasAPalikarasA. Changes in pupil reaction to light in Alzheimer's disease patients: a preliminary report. Int J Psychophysiol. (2000) 37:111–20. 10.1016/s0167-8760(00)00099-4
82.
FotiouDKaltsatouATsiptsiosDNakouM. Evaluation of the cholinergic hypothesis in Alzheimer's disease with neuropsychological methods. Aging Clin Exp Res. (2015) 27:727–33. 10.1007/s40520-015-0321-8
83.
FrostSRobinsonLRoweCCAmesDMastersCLTaddeiKet al. Evaluation of cholinergic deficiency in preclinical alzheimer's disease using pupillometry. J Ophthalmol. (2017) 2017:7935406. 10.1155/2017/7935406
84.
Van StavernGPBeiLShuiY-BHueckerJGordonM. Pupillary light reaction in preclinical Alzheimer's disease subjects compared with normal ageing controls. Br J Ophthalmol. (2018). 10.1136/bjophthalmol-2018-312425. [Epub ahead of print].
85.
TalesATrosciankoTLushDHaworthJWilcockGKButlerSR. The pupillary light reflex in aging and Alzheimer's disease. Aging. (2001) 13:473–8.
86.
GamlinPDRMcDougalDHPokornyJSmithVCYauK-WDaceyDM. Human and macaque pupil responses driven by melanopsin-containing retinal ganglion cells. Vis Res. (2007) 47:946–54. 10.1016/j.visres.2006.12.015
87.
MureLSCornutP-LRieuxCDrouyerEDenisPGronfierCet al. Melanopsin bistability: a fly's eye technology in the human retina. PLoS ONE. (2009) 4:e5991. 10.1371/journal.pone.0005991
88.
SunderlandTLinkerGMirzaNPutnamKTFriedmanDLKimmelLHet al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. (2003) 289:2094–103. 10.1001/jama.289.16.2094
89.
RoweCCEllisKARimajovaMBourgeatPPikeKEJonesGet al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. (2010) 31:1275–83. 10.1016/j.neurobiolaging.2010.04.007
90.
HaysMTWatsonEEThomasSRStabinM. MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG. J Nucl Med. (2002) 43:210–4.
91.
Santana P doCMourãoAPde OliveiraPMCBernardesFDMamedeMda SilvaTA. Dosimetry of patients submitted to cerebral PET/CT for the diagnosis of mild cognitive impairment. Radiol Bras. (2014) 47:350–4. 10.1590/0100-3984.2013.1800
92.
McDonaldRJ. Multiple combinations of co-factors produce variants of age-related cognitive decline: a theory. Can J Exp Psychol. (2002) 56:221–39. 10.1037/h0087399
93.
StrittmatterWJSaundersAMGoedertMWeisgraberKHDongLMJakesRet al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA. (1994) 91:11183–6. 10.1073/pnas.91.23.11183
94.
FrostSMKanagasingamYSohrabiHRTaddeiKBatemanRMorrisJet al. Pupil response biomarkers distinguish amyloid precursor protein mutation carriers from non-carriers. Curr Alzheimer Res. (2013) 10:790–6. 10.2174/15672050113109990154
95.
O'BryantSEHumphreysJDSmithGEIvnikRJGraff-RadfordNRPetersenRCet al. Detecting dementia with the mini-mental state examination (MMSE) in highly educated individuals. Arch Neurol. (2008) 65:963–7. 10.1001/archneur.65.7.963
96.
ScintoLFDaffnerKRDresslerDRansilBIRentzDWeintraubSet al. A potential noninvasive neurobiological test for Alzheimer's disease. Science. (1994) 266:1051–4.
97.
FitzSimonJSWaringSCKokmenEMcLarenJWBrubakerRF. Response of the pupil to tropicamide is not a reliable test for Alzheimer disease. Arch Neurol. (1997) 54:155–9. 10.1001/archneur.1997.00550140031009
98.
KurzAMarquardRFremkeSLeipertKP. Pupil dilation response to tropicamide: a biological test for Alzheimer's disease?Pharmacopsychiatry. (1997) 30:12–5.
99.
LoupeDNNewmanNJGreenRCLynnMJWIlliamsKKGeisTCet al. Pupillary response to tropicamide in patients with Alzheimer disease. Ophthalmology. (1996) 103:495–503. 10.1016/S0161-6420(96)30666-0
100.
WinnBWhitakerDElliottDBPhillipsNJ. Factors affecting light-adapted pupil size in normal human subjects. Invest Ophthalmol Vis Sci. (1994) 35:1132–7.
101.
AartsMPJRosemannALP. Towards a uniform specification of light therapy devices for the treatment of affective disorders and use for non-image forming effects: radiant flux. J Affect Disorders. (2018) 235:142–9. 10.1016/j.jad.2018.04.020
102.
BulloughJDReaMSFigueiroMG. Of mice and women: light as a circadian stimulus in breast cancer research. Cancer Causes Control. (2006) 17:375–83. 10.1007/s10552-005-0574-1
103.
AdhikariPPearsonCAAndersonAMZeleAJFeiglB. Effect of age and refractive error on the melanopsin mediated post-illumination pupil response (PIPR). Sci Rep. (2015) 5:17610. 10.1038/srep17610
104.
KankipatiLGirkinCAGamlinPD. Post-illumination pupil response in subjects without ocular disease. Invest Ophthalmol Vis Sci. (2010) 51:2764–9. 10.1167/iovs.09-4717
105.
HerbstKSanderBLund-AndersenHBroendstedAEKesselLHansenMSet al. Intrinsically photosensitive retinal ganglion cell function in relation to age: a pupillometric study in humans with special reference to the age-related optic properties of the lens. BMC Ophthalmol. (2012) 12:4. 10.1186/1471-2415-12-4
106.
SharmaSBaskaranMRukminiAVNongpiurMEHtoonHChengC-Yet al. Factors influencing the pupillary light reflex in healthy individuals. Graefes Arch Clin Exp Ophthalmol. (2016) 254:1353–9. 10.1007/s00417-016-3311-4
107.
RukminiAVMileaDGooleyJJ. Chromatic pupillometry methods for assessing photoreceptor health in retinal and optic nerve diseases. Front Neurol. (2019) 10:76. 10.3389/fneur.2019.00076
108.
KardonRAndersonSCDamarjianTGGraceEMStoneEKawasakiA. Chromatic pupillometry in patients with retinitis pigmentosa. Ophthalmology. (2011) 118:376–81. 10.1016/j.ophtha.2010.06.033
109.
LorenzBStrohmayrEZahnSFriedburgCKramerMPreisingMet al. Chromatic pupillometry dissects function of the three different light-sensitive retinal cell populations in RPE65 deficiency. Invest Ophthalmol Vis Sci. (2012) 53:5641–52. 10.1167/iovs.12-9974
110.
FeiglBZeleAJFaderSMHowesANHughesCEJonesKAet al. The post-illumination pupil response of melanopsin-expressing intrinsically photosensitive retinal ganglion cells in diabetes. Acta Ophthalmol. (2012) 90:e230–234. 10.1111/j.1755-3768.2011.02226.x
111.
ParkJCChenY-FBlairNPChauFYLimJILeidermanYIet al. Pupillary responses in non-proliferative diabetic retinopathy. Sci Rep. (2017) 7:44987. 10.1038/srep44987
112.
DeweyRB. Autonomic dysfunction in Parkinson's disease. Neurol Clin. (2004) 22 (Suppl. 3):S127–39. 10.1016/j.ncl.2004.05.006
113.
Perez-LloretSBarrantesFJ. Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease. NPJ Parkinsons Dis. (2016) 2:16001. 10.1038/npjparkd.2016.1
114.
MicieliGTassorelliCMartignoniEPacchettiCBruggiPMagriMet al. Disordered pupil reactivity in Parkinson's disease. Clinical Autonomic Research. (1991) 1:55–8.
115.
JainSSiegleGJGuCMooreCGIvancoLSJenningsJRet al. Autonomic insufficiency in pupillary and cardiovascular systems in Parkinson's disease. Parkinson Relat Disorders. (2011) 17:119–22. 10.1016/j.parkreldis.2010.11.005
116.
JoyceDSFeiglBKerrGRoederLZeleAJ. Melanopsin-mediated pupil function is impaired in Parkinson's disease. Sci Rep. (2018) 8:7796. 10.1038/s41598-018-26078-0
117.
BeachTGCarewJSerranoGAdlerCHShillHASueLIet al. Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neurosci Lett. (2014) 571:34–8. 10.1016/j.neulet.2014.04.027
118.
Bodis-WollnerIKozlowskiPBGlazmanSMiriS. α-synuclein in the inner retina in Parkinson disease. Ann Neurol. (2014) 75:964–6. 10.1002/ana.24182
119.
FerrariLHuangS-CMagnaniGAmbrosiAComiGLeocaniL. Optical coherence tomography reveals retinal neuroaxonal thinning in frontotemporal dementia as in Alzheimer's disease. J Alzheimers Dis. (2017) 56:1101–7. 10.3233/jad-160886
120.
KimBJIrwinDJSongDDanielELevequeJDRaquibARet al. Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. Neurology. (2017) 89:1604–11. 10.1212/WNL.0000000000004500
121.
DeBucDC. The role of retinal imaging and portable screening devices in tele-ophthalmology applications for diabetic retinopathy management. Curr Diab Rep. (2016) 16:132. 10.1007/s11892-016-0827-2
122.
RoeschKSwedishTRaskarR. Automated retinal imaging and trend analysis—a tool for health monitoring. Clin Ophthalmol. (2017) 11:1015–20. 10.2147/OPTH.S116265
123.
CoughlanGCoutrotAKhondokerMMinihaneAMSpiersHHornbergerM. Impact of sex and APOE status on spatial navigation in pre-symptomatic Alzheimer's disease. bioRxiv. (2018). 10.1101/287722. [Epub ahead of print].
124.
KatzSMarshallBL. Tracked and fit: FitBits, brain games, and the quantified aging body. J Aging Stud. (2018) 45:63–8. 10.1016/j.jaging.2018.01.009
Summary
Keywords
Alzheimer's disease, dementia, pupillary light response, chromatic pupillometry, melanopsin expressing intrinsically photosensitive retinal ganglion cells, Parkinson's disease, post -llumination pupil response, cholinergic deficit
Citation
Chougule PS, Najjar RP, Finkelstein MT, Kandiah N and Milea D (2019) Light-Induced Pupillary Responses in Alzheimer's Disease. Front. Neurol. 10:360. doi: 10.3389/fneur.2019.00360
Received
12 November 2018
Accepted
25 March 2019
Published
12 April 2019
Volume
10 - 2019
Edited by
Andrew J. Zele, Queensland University of Technology, Australia
Reviewed by
Shlomo Dotan, Hadassah Medical Center, Israel; Chiara La Morgia, IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB), Italy; Kathryn Ariel Roecklein, University of Pittsburgh, United States
Updates
Copyright
© 2019 Chougule, Najjar, Finkelstein, Kandiah and Milea.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Dan Milea dan.milea@snec.com.sg
This article was submitted to Neuro-Ophthalmology, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.